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COMPOSITIONS AND METHODS FOR subject assay . The definition encompasses blood and other 
DETECTING MYCOBACTERIUM liquid samples of biological origin , solid tissue samples such 
as a biopsy specimen or tissue cultures or cells derived CROSS - REFERENCE therefrom and the progeny thereof . The definition also 
5 includes samples that have been manipulated in any way This application claims the benefit of U . S . Provisional 
Patent Application No . 61 / 481 , 350 , filed May 2 , 2011 , after their procurement , such as by treatment with reagents , 
which application is incorporated herein by reference in its solubilization , or enrichment for certain components . The 
entirety . term “ biological sample ” encompasses a clinical sample , 
and also includes cells in culture , cell supernatants , cell 
STATEMENT REGARDING FEDERALLY lysates , serum , plasma , biological fluid , and tissue samples . 
SPONSORED RESEARCH A “ biological sample " can include biological fluids such as 
blood ; a blood fraction such as serum or plasma ; cerebro 
This invention was made with government support under spinal fluid ; pleural fluid ; bronchoalveolar lavage fluid ; and Grant No . 1R01A1073204 awarded by National Institutes of saliva . A “ biological sample ” can include a biological fluid Health . The government has certain rights in the invention . 15 that has been manipulated in any way . 
BACKGROUND The terms “ antibodies ” and “ immunoglobulin ” include antibodies or immunoglobulins of any isotype , fragments of 
Tuberculosis ( TB ) is an infectious disease that kills more antibodies which retain specific binding to antigen , includ 
adults than any other infectious disease worldwide . Every 20 ing , but not limited to , Fab , Fv , scFv , and Fd fragments , 
year , 8 . 9 - 9 . 9 million new cases of TB are estimated by the chimeric antibodies , humanized antibodies , single - chain 
World Health Organization to occur globally . The disease is antibodies , and fusion proteins comprising an antigen - bind 
caused by bacterium Mycobacterium tuberculosis , which ing portion of an antibody and a non - antibody protein . The 
can reside in an infected host for many years . Most infected antibodies may be detectably labeled , e . g . , with a radioiso people remain latently infected with the organism , but a 25 tope , an enzyme which generates a detectable product , a 
subset of infected individuals will reactivate the infection fluorescent protein , and the like . The antibodies may be and develop active disease . Timely treatment of those who further conjugated to other moieties , such as members of develop active disease is critical for preventing further specific binding pairs , e . g . , biotin ( member of biotin - avidin transmissions to others . Treatment requires reliable , rapid specific binding pair ) , and the like . The antibodies may also diagnosis of the disease . 
The problem is that in most countries endemic for TB . the 30 be bound to a solid support , including , but not limited to , 
diagnosis of the disease is hampered by the lack of resources polystyrene plates or beads , and the like . Also encompassed 
to culture the organism , which is especially needed to by the term are Fab ' , FV , F ( ab ) , and or other antibody 
diagnose drug - resistant forms of the disease . As such , in fragments that retain specific binding to antigen , and mono 
most countries , including in the United States , the treatment clonal antibodies . An antibody may be monovalent or biva 
of the disease is often initiated empirically , without the 35 lent . knowledge of the drug - susceptibility of the causative agent . “ Antibody fragments ” comprise a portion of an intact 
In someone who has drug - resistant TB , such a method of antibody , for example , the antigen binding or variable region 
treatment often fails . of the intact antibody . Examples of antibody fragments 
There is a need in the art for methods of determining include Fab , Fab ' , F ( ab ' ) , and Fv fragments ; diabodies ; 
whether an individual who is being treated for TB is 40 linear antibodies ( Zapata et al . , Protein Eng . 8 ( 10 ) : 1057 
responding to such treatment . 1062 ( 1995 ) ) ; single - chain antibody molecules ; and multi 
specific antibodies formed from antibody fragments . Papain SUMMARY digestion of antibodies produces two identical antigen 
binding fragments , called “ Fab ” fragments , each with a The present disclosure provides methods of detecting the 45 single antigen - binding site , and a residual “ Fc " fragment , a level of a mycobacterium in an individual , generally involv designation reflecting the ability to crystallize readily . Pep ing detecting antibody to a mycobacterial lipid in a biologi 
cal sample obtained from the individual . The present dis sin treatment yields an F ( ab ' ) , fragment that has two antigen 
closure further provides compositions and kits for carrying combining sites and is still capable of cross - linking antigen . 
out the methods . “ Axial flow ” as used herein refers to lateral , vertical or 50 transverse flow through a particular matrix or material 
BRIEF DESCRIPTION OF THE DRAWING comprising one or more test and / or control zones . The type 
of flow contemplated in a particular device , assay or method 
FIG . 1 depicts plots of the change of IgM anti - phospho varies according to the structure of the device . Without being 
lipids antibody levels after 40 doses of intense anti - TB drug bound by theory , lateral , vertical or transverse flow may 
therapy ( CL - cardiolipin , Pl - phosphatidylinositol , PE - phos - 55 refer to flow of a fluid sample from the point of fluid contact 
phatidylethanolamine , PTC - phosphatidylcholine , and SL on one end or side of a particular matrix ( the upstream or 
sphingolipid ) . proximal end ) to an area downstream ( or distal ) of this 
FIG . 2 is a schematic representation of a magnetic bead contact . The downstream area may be on the same side or on 
linked immunosorbent assay ( mLISA ) . the opposite side of the matrix from the point of fluid 
FIG . 3 depicts sample results of membranes from an 60 contact . For example , in vertical flow devices of the present 
mLISA ( OPD - patients with pulmonary disease other than invention , axial flow may progress vertically from and 
TB , PPD - patients testing positive for tuberculin skin test ) . through a first member top to bottom ) to a second member 
and from there on to an absorbent medium . By way of 
DEFINITIONS further example , and as will be appreciated by those of skill 
65 in the art , in a vertical flow device configured , for example , 
A “ biological sample ” encompasses a variety of sample as a dipstick , a fluid sample may flow literally up the device , 
types obtained from an individual and can be used in a in which case however , the point of first contact of the fluid 
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sample to the device is nonetheless considered the upstream noted that the claims may be drafted to exclude any optional 
( i . e . , proximal ) end and the point of termination of flow the element . As such , this statement is intended to serve as 
downstream ( i . e . , distal ) end . antecedent basis for use of such exclusive terminology as 
As used herein the terms " upstream ” and “ downstream ” “ solely , " " only ” and the like in connection with the recita 
refer to the direction of fluid sample flow subsequent to 5 tion of claim elements , or use of a “ negative " limitation . 
contact of the fluid sample with a representative device of It is appreciated that certain features of the invention , 
the present disclosure , wherein , under normal operating which are , for clarity , described in the context of separate 
conditions , the fluid sample flow direction runs from an embodiments , may also be provided in combination in a 
upstream position to a downstream position . For example , single embodiment . Conversely , various features of the 
when fluid sample is initially contacted with the sample 10 invention , which are , for brevity , described in the context of 
receiving zone , the fluid sample then flows downstream a single embodiment , may also be provided separately or in 
through the label zone and so forth . any suitable sub - combination . All combinations of the 
The term “ binding ” refers to a direct association between embodiments pertaining to the invention are specifically 
two molecules , due to , for example , covalent , electrostatic , embraced by the present invention and are disclosed herein 
hydrophobic , and ionic and / or hydrogen - bond interactions , 15 just as if each and every combination was individually and 
including interactions such as salt bridges and water bridges . explicitly disclosed , to the extent that such combinations 
An antibody specific for human IgM binds specifically to an embrace subject matter that are , for example , compounds 
epitope within a human IgM polypeptide ( e . g . , an epitope that are stable compounds ( i . e . , compounds that can be 
within the constant region of a human IgM polypeptide ) , made , isolated , characterized , and tested for biological activ 
e . g . , with an affinity of at least about 10 - 7 M , at least about 20 ity ) . In addition , all sub - combinations of the various 
10 - 8 M , at least about 10 - 9M , at least about 10 - 1°M , at least embodiments and elements thereof ( e . g . , elements of the 
about 10 - 11 M , or at least about 10 - 12 M , or greater than chemical groups listed in the embodiments describing such 
10 - 12 M . An antibody specific for human IgM binds to an variables ) are also specifically embraced by the present 
epitope present on a human IgM polypeptide with an affinity invention and are disclosed herein just as if each and every 
of from about 10 - 7 M to about 10 - 8 M , from about 10 - M 25 such sub - combination was individually and explicitly dis 
to about 10 - 9M , from about 10 - 9 M to about 10 - 10 M , from closed herein . 
about 10 - 10 M to about 10 - 11 M , or from about 10 - 11 M to The publications discussed herein are provided solely for 
about 10 - 12 M , or greater than 10 - 12 M . Non - specific bind their disclosure prior to the filing date of the present appli 
ing would refer to binding with an affinity of less than about cation . Nothing herein is to be construed as an admission 
10 - 7 M , e . g . , binding with an affinity of 10 - M , 10 - M , 30 that the present invention is not entitled to antedate such 
10 - 4 M , etc . publication by virtue of prior invention . Further , the dates of 
Before the present invention is further described , it is to publication provided may be different from the actual pub 
be understood that this invention is not limited to particular lication dates which may need to be independently con 
embodiments described , as such may , of course , vary . It is firmed . 
also to be understood that the terminology used herein is for 35 
the purpose of describing particular embodiments only , and DETAILED DESCRIPTION 
is not intended to be limiting , since the scope of the present 
invention will be limited only by the appended claims . The present disclosure provides methods of detecting the 
Where a range of values is provided , it is understood that level of a mycobacterium in an individual , generally involv 
each intervening value , to the tenth of the unit of the lower 40 ing detecting antibody to a mycobacterial lipid in a biologi 
limit unless the context clearly dictates otherwise , between cal sample obtained from the individual . The present dis 
the upper and lower limit of that range and any other stated closure further provides compositions and kits for carrying 
or intervening value in that stated range , is encompassed out the methods . 
within the invention . The upper and lower limits of these It was observed that antibody response to Mycobacterium 
smaller ranges may independently be included in the smaller 45 tuberculosis lipids is a direct reflection of bacterial burden in 
ranges , and are also encompassed within the invention , a host infected with M . tuberculosis . That is , higher the 
subject to any specifically excluded limit in the stated range . number of M . tuberculosis bacteria in a host , the higher the 
Where the stated range includes one or both of the limits , antibody level the host mounts to lipids produced by the 
ranges excluding either or both of those included limits are bacteria . A large proportion of the cell wall of M . tubercu 
also included in the invention . 50 losis is comprised of lipids . Thus , if treatment is successful , 
Unless defined otherwise , all technical and scientific the antibody response to the lipids decreases . This approach 
terms used herein have the same meaning as commonly makes it possible to apply a simple serologic test platform to 
understood by one of ordinary skill in the art to which this determine the M . tuberculosis burden in an infected indi 
invention belongs . Although any methods and materials vidual , and to determine an individual ' s response to treat 
similar or equivalent to those described herein can also be 55 ment for an M . tuberculosis infection . 
used in the practice or testing of the present invention , the Methods of Determining the Level of M . tuberculosis in an 
preferred methods and materials are now described . All Individual 
publications mentioned herein are incorporated herein by The present disclosure provides methods of detecting the 
reference to disclose and describe the methods and / or mate level of a mycobacterium ( e . g . , M . tuberculosis ) in an 
rials in connection with which the publications are cited . 60 individual . The methods generally involve determining the 
It must be noted that as used herein and in the appended level of IgM specific for an M . tuberculosis lipid in a 
claims , the singular forms “ a , " " an , ” and “ the ” include plural biological sample obtained from the individual . The level of 
referents unless the context clearly dictates otherwise . Thus , M . tuberculosis lipid - specific IgM is directly correlated with 
for example , reference to " a lipid " includes a plurality of the level of M . tuberculosis in the individual . 
such lipids and reference to “ the test device ” includes 65 Lipids 
reference to one or more test devices and equivalents thereof An M . tuberculosis lipid is a lipid that can be synthesized 
known to those skilled in the art , and so forth . It is further by M . tuberculosis . Lipids produced by M . tuberculosis 
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include , but are not limited to , cardiolipin , phosphati - bacterial lipid ( e . g . , cardiolipin ; phosphatidylethanolamine ; dylinositol , phosphatidylethanolamine , phosphatidylcho phosphatidylinositol ; phosphatidylcholine ; sphingolipid ; 
line , and sphingolipid . etc . ) is applied to a solid support , and any unbound lipid is 
Anti - IgM Antibody washed away , leaving immobilized lipid . A biological 
Anti - IgM antibody suitable for use in a subject method 5 sample from an individual is applied to the lipid - bound solid 
includes antibody specific for human IgM , e . g . , antibody support ; any IgM specific for a mycobacterial lipid that is 
specific for a constant region epitope of human IgM . In some present in the biological sample will bind to the lipid , 
cases , the anti - IgM antibody is a polyclonal antibody . In forming an immobilized IgM - lipid complex . Anti - IgM anti 
other cases , the anti - IgM antibody is a monoclonal antibody , body bound to a magnetic bead ( anti - IgM - magnetic bead ) is 
or an antigen - binding fragment thereof . 10 then contacted with the immobilized IgM - lipid complex . 
An anti - IgM antibody will in some embodiments com - Binding of the anti - IgM - magnetic bead to the immobilized 
prise a detectable label . Suitable detectable labels include IgM - lipid complex can be detected , e . g . , by visual inspec 
any composition detectable by spectroscopic , photochemi tion or any other suitable method . 
cal , biochemical , immunochemical , electrical , optical or Subjects 
chemical means . Suitable include , but are not limited to , 15 An individual who is to be tested using a subject method 
magnetic beads ( e . g . DynabeadsTM ) ; fluorescent dyes ( e . g . , includes individuals who have been diagnosed as having a 
fluorescein isothiocyanate , texas red , rhodamine , and the mycobacterial infection , e . g . , an infection with a mycobac 
like ) ; a fluorescent protein , e . g . , a green fluorescent protein , terium that is a pathogen . Individuals include humans and 
a red fluorescent protein , a yellow fluorescent protein , and non - human mammals ( e . g . , ungulates ( e . g . , bovines , ovines , 
the like ; a chromogenic polypeptide ; a radiolabel ( e . g . , ' H , 20 porcines , etc . ) , canines , felines , etc . ) . In many instances , the 
1251 , 35S , 14C , or 32P ) ; an enzyme that produces a colored individual is a human . 
product , a fluorescent product , or a luminescent product , In some instances , the individual is a human who has , or ( e . g . , horse radish peroxidase , alkaline phosphatase , is suspected of having , a mycobacterial infection , e . g . , an 
luciferase , and others commonly used in an enzyme - linked infection with Mycobacterium tuberculosis , M . bovis , M . 
immunosorbent assay ( ELISA ) ) ; and colorimetric labels 25 africanum , M . canetti , M . microti , M . leprae , M . marinum , 
such as colloidal gold or colored glass or plastic ( e . g . M . avium , or M . kansasii . Individuals who have , or who are 
polystyrene , polypropylene , latex , etc . ) beads . In some suspected of having , a mycobacterial infection can also 
cases , an anti - IgM antibody will comprise covalently linked include smokers ( e . g . , cigarette ( tobacco smokers ) , non 
colloidal gold . smokers , alcoholics , non - alcoholics , illegal drug users , non 
In some cases , an anti - IgM antibody will be linked to a 30 drug users , individuals infected with human immunodefi 
magnetic bead . As one non - limiting example , an anti - IgM ciency virus ( HIV ) , individuals not infected with HIV , 
antibody can be covalently linked to biotin ; a magnetic bead individuals with a healthy immune system , and immuno 
can be coated with streptavidin ; and the anti - IgM - biotin can compromised individuals . In some instances , the individual 
bind to the streptavidin - magnetic bead , to form a stable is apparently healthy ; in other instance , the individual exhib 
anti - IgM - magnetic bead complex . Other means of linking an 35 its one or more symptoms of a mycobacterial infection . 
anti - IgM antibody to a magnetic bead are known in the art ; In some instances , the individual is a human infected with 
and any such means can be used . For example , Protein Gcan Mycobacterium tuberculosis . The individual can be a human 
be bound to ( e . g . , cross - linked to ) a magnetic bead , and an who has an M . tuberculosis infection , and who has been 
anti - IgM antibody capable of binding to Protein G can be treated with a first - line drug for treating an M . tuberculosis 
complexed with the Protein - G - magnetic bead . As another 40 infection . The individual can be a human who has an M . 
example , Protein A can be bound to ( e . g . , cross - linked to ) a tuberculosis infection , and who has been treated with a 
magnetic bead , and an anti - IgM antibody capable of binding second - line drug for treating an M . tuberculosis infection . 
to Protein A can be complexed with the Protein - A - magnetic The individual can be a human who has an M . tuberculosis 
bead . infection , and who has been treated with a third - line drug for 
Assay Formats 45 treating an M . tuberculosis infection . 
A subject method can be carried out using any of a variety First - line drugs for treating an M . tuberculosis infection 
of assay formats . For example , in some instances , lipids are include ethambutol , isoniazid , pyrazinamide , rifampicin , 
attached to an insoluble support . Suitable insoluble supports and streptomycin . An example of a treatment regimen 
can comprise various materials including , but not limited to , including first - line drugs is isoniazid , rifampicin , ethambu 
polyvinyl difluoride ( PVDF ) , cellulose , nitrocellulose , 50 tol , and pyrazinamide daily for two months ; followed by 
nylon , glass , polystyrene , polyvinyl chloride , polypropyl - four months of isoniazid and rifampicin three times per 
ene , polyester terephthalate , polyethylene , polycarbonate , week . Second - line drugs for treating an M . tuberculosis 
dextran , amylose , natural and modified celluloses , polyacry - infection include aminoglycosides ( e . g . , amikacin ; kanamy 
lamides , silica embedded in a polyacrylamide gel , agaroses , cin ) ; polypeptides such as capreomycin , viomycin , and 
and magnetite and the like . 55 enviomycin , fluoroquinolines such as ciprofloxacin , levo 
The insoluble support can be in any of a variety of formats floxacin , moxifloxacin ; thioamides such as ethionamide and ( e . g . , dimensions , shapes ) , e . g . , sheets , such as used in a test prothionamide ; cycloserine ; and p - aminosalicylic acid . 
strip or dipstick assay format . Third - line drugs for treating an M . tuberculosis infection 
Methods for attaching a lipid to an insoluble support include rifabutin ; macrolides such as clarithromycin ; lin 
include , e . g . , direct attachment of the lipid to an insoluble 60 ezolid ; thioacetazone ; thioridazine ; arginine ; vitamin D ; and 
support ; modification of a lipid with a linker moiety , which R207910 . 
linker moiety ( e . g . , a peptide ) serves as the attachment point In some instances , the individual is one who has been 
to the insoluble support ; etc . A lipid ( modified to include a treated for an M . tuberculosis infection with a first - line drug 
linker moiety ; or unmodified ) can be covalently or non - or combination of first - line drugs ; and who has become 
covalently linked to an insoluble support . 65 resistant to the first - line drug or the combination of first - line 
In some cases , the assay format is a magnetic bead - linked drugs , e . g . , M . tuberculosis resistant to the first - line drug 
immunosorbent assay ( mLISA ) . As an example , a myco emerges in the individual . In some instances , the individual 
US 9 , 835 , 624 B2 
is infected with drug - resistant M . tuberculosis . For example , recommendations ; 5 ) therapeutic intervention recommenda 
in some instances , the individual is infected with isoniazid tions ; and 6 other features . A subject report can include , in 
resistant M . tuberculosis . In some instances , the individual is addition to information regarding the level of mycobacteria 
infected with a multi - drug resistant strain of M . tuberculosis . ( as determined by the level of mycobacterial lipid - specific 
Individuals also include individuals who have an M . 5 IgM ) , patient information such as age , gender , body mass 
tuberculosis infection or an infection with a mycobacterium index ( BMI ), bilateral abnormalities , acid - fast bacillus 
other than M . tuberculosis , and who have one or more other ( AFB ) smear status , cavitary disease , and disease severity . 
disorders . For example , individuals who may be tested with Based on the determined level of mycobacteria , and / or 
a subject method include individuals who have an M . based on a report ( as described above ) , a physician or other 
tuberculosis infection ; and who are infected with a human 10 qualified medical personnel can determine whether appro 
immunodeficiency virus ( HIV ) , e . g . , HIV - 1 . Individuals priate modification in therapeutic regimen is advised . 
who may be tested with a subject method include individuals Utility 
who have silicosis ; and who have an M . tuberculosis infec - A subject detection method finds use in various applica 
tion . Individuals who may be tested with a subject method tions . For example , the present disclosure provides methods 
include individuals who are immunocompromised ; and who 15 of determining the response of an individual to treatment for 
have an M . tuberculosis infection . an M . tuberculosis infection . As another example , the pres 
Individuals who are suitable for testing using a subject ent disclosure provides methods of detecting the presence of 
method also include : 1 ) individuals with confirmed tuber M . tuberculosis in an individual ; e . g . , methods of determin 
culosis ( verified TB cases ) , who have non - cavitary lung ing whether an individual has an M . tuberculosis infection . 
disease as evidenced by , e . g . , chest x - ray ; 2 ) individuals with 20 Methods of Determining Response to Drug Treatment 
confirmed tuberculosis with cavitary lung disease as evi The present disclosure provides methods of determining 
denced by , e . g . , chest x - ray ; 3 ) individuals with extra - the response of an individual to treatment for an M . tuber 
pulmonary tuberculosis ; 4 ) individuals who are close con - culosis infection . The methods generally involve determin 
tacts of an individual with confirmed tuberculosis ( e . g . , ing the level of IgM specific for an M . tuberculosis lipid in 
individuals who come into physical proximity with an 25 a biological sample obtained from the individual . A biologi 
individual with confirmed tuberculosis ) , where such close - cal sample is obtained from an individual undergoing treat 
contact individuals include , e . g . , household contacts , school - ment for a mycobacterial infection ; and the biological 
mates , co - workers , and friends ; 5 ) individuals who are sample is tested to determine the level of IgM specific for an 
shown to have latent tuberculosis infection ( M . tuberculosis M . tuberculosis lipid . 
infection ) based on positive tuberculin skin test and / or 30 level of M . tuberculosis lipid - specific IgM in the 
gamma interferon release assays ; 6 ) individuals with latent biological sample that is lower than a pre - treatment level 
M . tuberculosis infection , who are undergoing preventive indicates that the individual is responding positively to the 
treatment for the infection ; 7 ) Bacille Calmette - Guérin treatment . For example , a level of M . tuberculosis lipid 
( BCG ) - vaccinated individuals ; 8 ) individuals with mono - specific IgM in the biological sample that is at least about 
resistant TB ( e . g . , individuals infected with M . tuberculosis 35 10 % , at least about 15 % , at least about 20 % , at least about 
that is resistant to a single drug used to treat M . tuberculosis 25 % , at least about 30 % , at least about 35 % , at least about 
infection ) ; 9 ) individuals with multidrug - resistant TB ( e . g . , 40 % , or at least about 50 % , or more than 50 % , lower than 
individuals infected with M . tuberculosis that is resistant to a pre - treatment level indicates that the individual is respond 
two or more drugs used to treat M . tuberculosis infection ) ; ing positively to the treatment . 
and 10 ) individuals with extensively drug resistant ( XDR ) 40 Alternatively , a level of M . tuberculosis lipid - specific IgM 
TB ( e . g . , individuals infected with XDR M . tuberculosis ) . in a biological sample obtained at a first time point during 
Individuals suitable for testing using a subject method treatment for the M . tuberculosis infection is compared with 
include : 1 ) individuals with mono - resistant TB ( e . g . , indi the level of M . tuberculosis lipid - specific IgM in a biological 
viduals infected with M . tuberculosis that is resistant to a sample obtained at a second time point during treatment for 
single drug used to treat M . tuberculosis infection ) , which 45 the M . tuberculosis infection , where the second time point is 
individuals are undergoing treatment for the M . tuberculosis later than the first time point . Where the level of M . 
infection ; 2 ) individuals with multidrug - resistant TB ( e . g . , tuberculosis lipid - specific IgM is lower at the second time 
individuals infected with M . tuberculosis that is resistant to point than at the first time point indicates that the individual 
two or more drugs used to treat M . tuberculosis infection ) , is responding positively to the treatment . For example , a 
which individuals are undergoing treatment for the M . 50 level of M . tuberculosis lipid - specific IgM in a biological 
tuberculosis infection ; and 3 ) individuals with XDR TB sample obtained at a second time point that is at least about 
( e . g . , individuals infected with XDR M . tuberculosis ) , which 10 % , at least about 15 % , at least about 20 % , at least about 
individuals are undergoing treatment for the M . tuberculosis 25 % , at least about 30 % , at least about 35 % , at least about 
infection . Treatments include those described above . 40 % , or at least about 50 % , or more than 50 % , lower than 
Generating a Report 55 the level of M . tuberculosis lipid - specific IgM in a biological 
A subject method can include generating a report that sample obtained at a first time point indicates that the 
provides an indication of the level of mycobacteria in an individual is responding positively to the treatment . The 
individual . For example , the methods disclosed herein can time period between the first time point and the second 
further include a step of generating or outputting a report ( later ) time point can be from about 1 day to about 1 year ( or 
providing the results of a subject detection method , which 60 more than 1 year ) , e . g . , from about 1 day to about 7 days , 
report can be provided in the form of an electronic medium from about 1 week to about 2 weeks , from about 2 weeks to 
( e . g . , an electronic display on a computer monitor ) , or in the about 4 weeks , from about 1 month to about 2 months , from 
form of a tangible medium ( e . g . , a report printed on paper or about 2 months to about 6 months , or from about 6 months 
other tangible medium ) . to about 1 year , or more than 1 year . 
A subject report can further include one or more of : 1 ) 65 Subjects 
service provider information ; 2 ) patient data ; 3 ) data regard An individual who is to be tested using a subject method 
ing the level of mycobacteria ; 4 ) follow - up evaluation includes an individual who has a mycobacterial infection 
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( e . g . , an infection with Mycobacterium tuberculosis , M . infection ; 4 ) follow - up evaluation recommendations ; 5 ) 
bovis , M . africanum , M . canetti , M . microti , M . leprae , M . therapeutic intervention recommendations , and 6 other fea 
marinum , M . avium , or M . kansasii ) ( e . g . , an individual who tures . A subject report can include , in addition to information 
has tested positive for a mycobacterial infection , e . g . , using regarding the level of mycobacteria ( as determined by the 
a PPD skin test ) ; and who is undergoing treatment for the 5 level of mycobacterial lipid - specific IgM ) , patient informa 
infection . tion such as age , gender , body mass index ( BMI ) , bilateral 
In some instances , the individual is a human infected with abnormalities , acid - fast bacillus ( AFB ) smear status , cavi 
Mycobacterium tuberculosis . The individual can be a human tary disease , and disease severity . 
who has an M . tuberculosis infection , and who has been Based on the assessment of the individual ' s response to 
treated with a first - line drug for treating an M . tuberculosis 10 drug treatment for a mycobacterial infection , and / or based 
infection . The individual can be a human who has an M . on a report ( as described above ) , a physician or other 
tuberculosis infection , and who has been treated with a qualified medical personnel can determine whether appro 
second - line drug for treating an M . tuberculosis infection . priate modification in therapeutic regimen is advised . 
The individual can be a human who has an M . tuberculosis Diagnostic Methods 
infection , and who has been treated with a third - line drug for 15 The present disclosure provides methods of detecting the 
treating an M . tuberculosis infection . presence of M . tuberculosis in an individual . The presence of 
First - line drugs for treating an M . tuberculosis infection M . tuberculosis in an individual can indicate that the indi 
include ethambutol , isoniazid , pyrazinamide , rifampicin , vidual has an M . tuberculosis infection . Thus , the present 
and streptomycin . An example of a treatment regimen disclosure provides methods of determining whether an 
including first - line drugs is isoniazid , rifampicin , ethambu - 20 individual has an M . tuberculosis infection . The methods 
tol , and pyrazinamide daily for two months ; followed by generally involve determining the level of IgM specific for 
four months of isoniazid and rifampicin three times per an M . tuberculosis lipid in a biological sample obtained from 
week . Second - line drugs for treating an M . tuberculosis the individual . 
infection include aminoglycosides ( e . g . , amikacin ; kanamy . Thus , the present disclosure provides a method for detect 
cin ) ; polypeptides such as capreomycin , viomycin , and 25 ing the presence of Mycobacterium tuberculosis in an indi 
enviomycin ; fluoroquinolines such as ciprofloxacin , levo - vidual , the method comprising detecting IgM specific for a 
floxacin , moxifloxacin ; thioamides such as ethionamide and Mycobacterium tuberculosis lipid in a liquid biological 
prothionamide ; cycloserine ; and p - aminosalicylic acid . sample obtained from the individual . The presence in the 
Third - line drugs for treating an M . tuberculosis infection biological sample of IgM specific for a Mycobacterium 
include rifabutin ; macrolides such as clarithromycin ; lin - 30 tuberculosis lipid indicates the presence in the individual of 
ezolid ; thioacetazone ; thioridazine ; arginine ; vitamin D ; and Mycobacterium tuberculosis . 
R207910 . A level of M . tuberculosis lipid - specific IgM in the 
In some instances , the individual is one who has been biological sample that is higher than a normal , control level 
treated for an M . tuberculosis infection with a first - line drug indicates the presence of M . tuberculosis in the individual , 
or combination of first - line drugs ; and who has become 35 and can indicate that the individual has an M . tuberculosis 
resistant to the first - line drug or the combination of first - line infection . For example , a level of M . tuberculosis lipid 
drugs , e . g . , M . tuberculosis resistant to the first - line drug specific IgM in the biological sample that is at least about 
emerges in the individual . In some instances , the individual 20 % , at least about 25 % , at least about 30 % , at least about 
is infected with drug - resistant M . tuberculosis . For example , 35 % , at least about 40 % , at least about 50 % , at least about 
in some instances , the individual is infected with isoniazid - 40 2 - fold , at least about 5 - fold , or more than 5 - fold , higher than 
resistant M . tuberculosis . In some instances , the individual is a normal , control level indicates the presence of M . tuber 
infected with a multi - drug resistant strain of M . tuberculosis . culosis in the individual , and can indicate that the individual 
Individuals also include individuals who have an M . has an M . tuberculosis infection . 
tuberculosis infection or an infection with a mycobacterium A normal , control level of M . tuberculosis lipid - specific 
other than M . tuberculosis , and who have one or more other 45 IgM is a level , or a range of levels , that is found in 
disorders . For example , individuals who may be tested with individuals who have tested negative for M . tuberculosis 
a subject method include individuals who have an M . infection , using , e . g . , a tuberculosis skin test ( also known as 
tuberculosis infection ; and who are infected with a human the “ purified protein derivative ” or “ PPD ” tuberculin skin 
immunodeficiency virus ( HIV ) , e . g . , HIV - 1 . Individuals test ) . 
who may be tested with a subject method include individuals 50 Subjects 
who have silicosis ; and who have an M . tuberculosis infec Subjects who can undergo a subject diagnostic method to 
tion . Individuals who may be tested with a subject method determine the presence of M . tuberculosis include individu 
include individuals who are immunocompromised ; and who als who have never previously been tested for M . tubercu 
have an M . tuberculosis infection . losis infection ; individuals who have been previously tested 
Generating a Report 55 ( e . g . , using the PPD tuberculin skin test ) for M . tuberculosis 
A subject method can include generating a report that infection ; individuals who are at greater risk than the general 
provides an indication of an individual ' s response to drug population of having an M . tuberculosis infection . Individu 
treatment for a mycobacterial infection . For example , the als who are at greater risk than the general population of 
methods disclosed herein can further include a step of having an M . tuberculosis infection include , e . g . , HIV - 1 
generating or outputting a report providing the results of a 60 infected individuals ; long - term alcohol or drug abusers ; 
subject diagnostic method , which report can be provided in immunocompromised individuals ; individuals who fre 
the form of an electronic medium ( e . g . , an electronic display quently travel to or who have travelled to countries in which 
on a computer monitor ) , or in the form of a tangible medium the rate of tuberculosis is high ; individuals living in crowded 
( e . g . , a report printed on paper or other tangible medium ) . facilities ( e . g . , prisons ) ; and the like . 
A subject report can further include one or more of : 1 ) 65 Treatment 
service provider information ; 2 ) patient data ; 3 ) data regard - In some cases , an individual who is diagnosed as having 
ing the response to drug treatment for a mycobacterial an M . tuberculosis infection , using a subject detection 
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method , is then treated for the M . tuberculosis infection . For panel of lipids comprises cardiolipin , phosphatidylinositol , 
example , the individual can be treated with a first - line drug phosphatidylethanolamine , phosphatidylcholine , and sphin 
for treating an M . tuberculosis infection . golipid . 
First - line drugs for treating an M . tuberculosis infection In some embodiments , a subject kit includes purified 
include ethambutol , isoniazid , pyrazinamide , rifampicin , 5 mycobacterial lipids , e . g . , where the lipids are provided at 
and streptomycin . An example of a treatment regimen greater than 90 % purity , greater than 95 % purity , greater 
including first - line drugs is isoniazid , rifampicin , ethambu than 98 % purity , or greater than 99 % purity . For example , 
tol , and pyrazinamide daily for two months ; followed by the kit can include one or more of cardiolipin , phosphati 
four months of isoniazid and rifampicin three times per dylinositol , phosphatidylethanolamine , phosphatidylcho 
week . Second - line drugs for treating an M . tuberculosis 10 line , and sphingolipid in purified form . In some instances , a subject kit includes cardiolipin , phosphatidylinositol , phos infection include aminoglycosides ( e . g . , amikacin ; kanamy phatidylethanolamine , phosphatidylcholine , and sphingo cin ) ; polypeptides such as capreomycin , viomycin , and lipid in purified form . In some instances , a subject kit enviomycin ; fluoroquinolines such as ciprofloxacin , levo includes purified mycobacterial lipids immobilized on an floxacin , moxifloxacin ; thioamides such as ethionamide and 15 insoluble support . prothionamide ; cycloserine ; and p - aminosalicylic acid . The lipids can be obtained from a variety of sources . For 
Third - line drugs for treating an M . tuberculosis infection example , the lipids can be obtained from mycobacteria ( e . g . , 
include rifabutin ; macrolides such as clarithromycin ; lin - purified from mycobacteria ) ; the lipids can be obtained from 
ezolid ; thioacetazone ; thioridazine ; arginine ; vitamin D ; and mammalian host cells ( e . g . , from mammalian host cells 
R207910 . 20 infected with a mycobacterium ) ; or the lipids can be 
Generating a Report obtained from commercial sources . Thus , the term “ myco 
A subject method can include generating a report that bacterial lipid ” refers to a lipid that is associated with a 
indicates whether an individual has a mycobacterial infec mycobacterium and can be synthesized by a mycobacterium . 
tion ( e . g . , an M . tuberculosis infection ) . For example , the However , the term “ mycobacterial lipid does not limit the 
methods disclosed herein can further include a step of 25 source of the lipid to mycobacteria . 
generating or outputting a report providing the results of a In some cases , the binding agent that specifically binds 
subject diagnostic method , which report can be provided in human IgM is an antibody . Suitable antibodies include 
the form of an electronic medium ( e . g . , an electronic display monoclonal antibodies , and antigen - binding fragments ( e . g . , 
on a computer monitor ) , or in the form of a tangible medium a Fv , scFv , Fab , F ( ab ' ) 2 , or Fab ' fragment ) . Where the ( e . g . , a report printed on paper or other tangible medium ) . 30 binding reagent is an antibody , the antibody can be immo 
A subject report can further include one or more of : 1 ) bilized on an insoluble support ( e . g . , a test strip , a well of a 
service provider information ; 2 ) patient data ; 3 ) presence or multi - well plate , beads , etc . ) . Where the binding reagent is 
absence of a mycobacterial infection ; 4 ) follow - up evalua - an antibody , the antibody can comprise a detectable label . 
tion recommendations ; 5 ) therapeutic intervention recom Where the antibody comprises a detectable label , a subject 
mendations ; and 6 other features . A subject report can 35 kit can include one or more reagents for developing the 
include , in addition to information regarding the level of detectable label . A labeled antibody can comprise a label 
mycobacteria ( as determined by the level of mycobacterial such as a chemiluminescent agent , a particulate label ( e . g . , 
lipid - specific IgM ) , patient information such as age , gender , colloidal gold ) , a magnetic bead , a colorimetric agent , an 
body mass index ( BMI ), bilateral abnormalities , acid - fast energy transfer agent , an enzyme , a fluorescent agent , or a 
bacillus ( AFB ) smear status , cavitary disease , and disease 40 radioisotope . A subject kit can include an anti - IgM antibody 
severity . coupled to a magnetic bead . 
Based on an assessment of the presence in the individual Other optional components of the kit include : a buffer ; a 
of a mycobacterial infection , and / or based on a report ( as protease inhibitor ; a lipase inhibitor ; a detectable label ; etc . 
described above ) , a physician or other qualified medical The various components of the kit may be present in 
personnel can determine an appropriate therapeutic regimen . 45 separate containers or certain compatible components may 
Kits and Assay Devices be pre - combined into a single container , as desired . 
The present disclosure provides a kit for carrying out a A subject kit can include a solid support ( also referred to 
method of the present disclosure , e . g . , a method of detecting , herein as an “ insoluble support ” ) . Suitable insoluble sup 
in a biological sample obtained from an individual , the level ports can comprise various materials including , but not 
of IgM specific for a mycobacterial lipid . The present 50 limited to , PVDF , cellulose , nitrocellulose , nylon , glass , 
disclosure further provides an assay device for carrying out polystyrene , polyvinyl chloride , polypropylene , polyester 
a method of the present disclosure , e . g . , a method of terephthalate , polyethylene , polycarbonate , dextran , amy 
detecting , in a biological sample obtained from an indi - lose , natural and modified celluloses , polyacrylamides , silica 
vidual , the level of IgM specific for a mycobacterial lipid . embedded in a polyacrylamide gel , agaroses , and magnetite 
Kits 55 and the like . 
A subject kit can include : a ) a binding reagent ( e . g . , an In addition to above - mentioned components , a subject kit 
antibody ) that specifically binds human IgM ; b ) one or more can include instructions for using the components of the kit 
mycobacterial lipids ; and c ) a control ( e . g . , a positive to practice a subject method . The instructions for practicing 
control ; a negative control ) . A subject kit can also include a subject method are generally recorded on a suitable 
purified human IgM for use in generating a standard curve , 60 recording medium . For example , the instructions may be 
e . g . , where the purified human IgM is provided in known printed on a substrate , such as paper or plastic , etc . As such , 
amount that can be diluted to generate a standard curve . A the instructions may be present in the kits as a package 
subject kit can include a panel of positive control IgM insert , in the labeling of the container of the kit or compo 
antibodies specific for the lipids in the panel . In some cases , nents thereof ( i . e . , associated with the packaging or sub 
the positive - control IgM antibodies can comprise a detect - 65 packaging ) etc . In other embodiments , the instructions are 
able label . A subject kit can include an insoluble support present as an electronic storage data file present on a suitable 
having a panel of mycobacterial lipids attached thereto . The computer readable storage medium , e . g . compact disc - read 
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only memory ( CD - ROM ) , digital versatile disk ( DVD ) , The labeled antibody can comprise a label such as a 
diskette , etc . In yet other embodiments , the actual instruc - chemiluminescent agent , a particulate label ( e . g . , colloidal 
tions are not present in the kit , but means for obtaining the gold ) , a colorimetric agent , an energy transfer agent , an 
instructions from a remote source , e . g . via the internet , are enzyme , a fluorescent agent , or a radioisotope . 
provided . An example of this embodiment is a kit that 5 Control zones include positive control zones and negative 
includes a web address where the instructions can be viewed control zones . 
and / or from which the instructions can be downloaded . As The matrix is generally an insoluble support , where 
with the instructions , this means for obtaining the instruc suitable insoluble supports include , but are not limited to , 
tions is recorded on a suitable substrate . polyvinyl difluoride ( PVDF ) , polyester terephthalate , cellu 
Assay Device 10 lose , nitrocellulose , polystyrene , nylon , silica embedded in 
The present disclosure further provides an assay device polyacrylamide , and the like . The matrix can be flexible , or 
for use in detecting , in a liquid biological sample obtained can be relatively inflexible . The matrix can be positioned 
from an individual , IgM specific for a mycobacterial lipid . within a housing comprising a support and optionally a 
The device can include a matrix defining an axial flow path . 15 cover , where the housing contains an application aperture 15 and one or more observation ports . The assay device can be The matrix can comprise : i ) a sample receiving zone at an in any of a variety of formats , e . g . , a test strip , a dipstick ; etc . upstream end of the flow path that receives the liquid 
sample ; ii ) one or more test zones positioned within the flow EXAMPLES path and downstream from the sample receiving zone , each 
of the one or more test zones comprising a different myco - 20 The following examples are put forth so as to provide 
bacterial lipid immobilized therein , where each of the immo those of ordinary skill in the art with a complete disclosure bilized mycobacterial lipids is capable of binding mycobac - and description of how to make and use the present inven 
terial lipid - specific IgM present in the liquid sample , to form tion , and are not intended to limit the scope of what the 
an immobilized mycobacterial lipid - specific IgM ; and iii ) inventors regard as their invention nor are they intended to 
one or more control zones positioned within the flow path 25 represent that the experiments below are all or the only 
and downstream from the sample receiving zone , where the experiments performed . Efforts have been made to ensure 
one or more control zones can include positive and / or accuracy with respect to numbers used ( e . g . amounts , tem 
negative controls . The test zones and control zones can be perature , etc . ) but some experimental errors and deviations 
positioned in an alternating format within the flow path should be accounted for . Unless indicated otherwise , beginning with a test zone positioned upstream of any 30 parts are parts by weight , molecular weight is weight aver 
control zone . age molecular weight , temperature is in degrees Celsius , 
Control zones can include , e . g . , human IgM ( e . g . , purified and pressure is at or near atmospheric . Standard abbrevia tions may be used , e . g . , bp , base pair ( s ) ; kb , kilobase ( s ) ; human IgM ) in known amounts , e . g . , for use in generating 
a standard curve , such that the amount of mycobacterial pl , picoliter ( s ) ; s or sec , second ( s ) ; min , minute ( s ) ; h or 35 hr , hour ( s ) ; aa , amino acid ( s ) ; kb , kilobase ( s ) ; bp , base lipid - specific human IgM in a liquid biological sample can pair ( s ) ; nt , nucleotide ( s ) ; i . m . , intramuscular ( ly ) ; i . p . , intra be quantitated . peritoneal ( ly ) ; s . c . , subcutaneously ) ; and the like . In using such an assay device , in some embodiments , a 
labeled antibody specific for human IgM can first be mixed Example 1 : Detection of Antibodies to M . 
with a liquid sample before the liquid sample is applied to 40 tuberculosis Lipids in Humans 
the sample receiving zone of the device , where such mixing 
results in a labeled antibody / human IgM complex . In these Materials and Methods 
embodiments , the liquid sample comprising the labeled Patient Specimens 
antibody / human IgM complex is applied to the sample Serum samples were obtained at baseline ( before initia 
receiving zone of the assay device . The liquid sample flows 45 tion of drug therapy and at the end of the intensive phase of 
along the device until the liquid sample reaches a test zone . therapy from 40 HIV - negative patients with acid - fast bacilli 
Lipid present in the test zone binds mycobacterial lipid ( AFB ) smear and culture - confirmed pulmonary tuberculosis 
specific human IgM present in the labeled antibody / human ( PTB ) . These patients were enrolled in a study of the Center 
IgM complex ; and can then be detected . for Disease Control and Prevention - Tuberculosis Trials 
The assay device can further include a label zone com - 50 Consortium ( CDC - TBTC ) randomized clinical trial con 
prising a labeled antibody specific for human IgM , wherein ducted in Kampala , Uganda . The patient cohort was equally 
the labeled antibody is capable of binding an IgM present in composed of two groups : 20 culture - positive patients ( slow 
an immobilized IgM - lipid complex to form a labeled immo - responders ) and 20 culture - negative patients ( fast respond 
bilized IgM - lipid complex , and wherein the labeled antibody ers ) at the end of 40 doses of anti - TB combination treatment , 
is mobilizable in the presence of liquid sample . In using such 55 which corresponds to eight weeks of treatment ( 5 doses per 
an assay device , a liquid sample comprising mycobacterial week ) . Patients were further categorized according to dis 
lipid - specific human IgM is applied to the sample receiving ease severity , based on the extent of radiological findings in 
zone of the device ; antibody present in the label zone binds chest X - ray at TB diagnosis including : limited , moderate , 
the mycobacterial lipid - specific human IgM , forming and extensive ; and whether or not cavitary lesions were 
labeled antibody / mycobacterial lipid - specific human IgM 60 present : cavity and no cavity . Serum samples were screened 
complex , which , like the labeled antibody , is mobilizable ; for levels of IgM antibodies against five phospholipids 
and the labeled antibody / mycobacterial lipid - specific human extracted from bovine sources available commercially 
IgM complex flows along the device until the liquid sample ( Avanti Polar Lipids , Ala . , USA ) . 
reaches a test zone . Lipid present in the test zone binds Enzyme - Linked Immunosorbent Assay ( ELISA ) 
mycobacterial lipid - specific human IgM present in the 65 The phospholipid antigens included cardiolipin ( CL ) , 
labeled antibody / mycobacterial lipid - specific human IgM phosphatidylinositol ( PI ) , phosphatidylethanolamine ( PE ) , 
complex ; and can then be detected . phosphatidylcholine ( PTC ) , and sphingolipid ( SL ) . Lipids 
16 
2 
30 Limited 
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were diluted to 10 mg / ml in ethanol and 50 ul of the TABLE 1 
solutions were dried overnight in flat bottom well polysty 
rene ELISA plates ( Fisher Scientific , USA ) . ELISA plates Demographic and clinical characteristics of TB patients who responded early ( sputum culture negative at 8 weeks of treatment ) and late 
were blocked with 100 ul of 3 % low fatty acid bovine serum ( sputum culture positive at 8 weeks ) . 
albumin ( BSA ) ( USBiologicals , USA ) and washed with 5 
phosphate buffered saline ( PBS ) pH 7 . 4 . Frozen serum Culture Culture 
negative at positive at 
samples were thawed twice and diluted 1 : 100 in 3 % low 8 weeks ( n = 20 ) 8 weeks ( n = 20 ) fatty acid BSA . The diluted sample was added to the plate 
and incubated for one hour at room temperature ( RT ) , Demographic characteristics 
followed by three washes with PBS . Then , 100 ul of 1 : 5 , 000 10 Age ; median ( IQR ) 25 . 0 ( 6 . 0 ) 30 . 0 ( 4 . 0 ) 
goat - derived anti - human IgM labeled with horse radish Male gender 13 ( 65 % ) 16 ( 85 % ) 
peroxidase ( HRP ) ( Thermo Scientific , Ill ) diluted in PBS PH Social characteristics 
7 . 4 was added , followed by incubation at RT for 1 hr and Smoking history 4 ( 20 % ) 5 ( 25 % ) 
washed again with PBS . Finally , 100 ul of tetramethylben - 16 Past alcohol use 0 ( 0 % ) 1 ( 5 % ) 
zidine substrate ( TMB ) ( Thermo Scientific Pierce , 111 . , USA ) Past drug use ( injection ) 0 ( 0 % ) 0 ( 0 % ) Past drug use ( non - injection ) 0 ( 0 % ) 1 ( 5 % ) was added and the reaction was stopped immediately with Clinical characteristics 50 ul of sulfuric acid 1M . 
Reactions were read within ten minutes at 450 nm in a BMI ;median ( IQR ) 19 . 8 ( 2 . 8 ) 18 . 6 ( 2 . 5 ) 
HIV infected 0 ( 0 % ) 0 ( 0 % ) spectrophotometer ( Cambridge Technologies , Massachu - 20 Any co - morbid condition 1 ( 5 % ) 0 ( 0 % ) 
setts ) . The results were read out as the average of optical TB diagnosis 
densities ( O . D . ) of triplicate assays . Standards curves for the Any cavity ELISA were prepared with polyclonal human IgM ( Thermo 12 ( 60 % ) 11 ( 55 % ) Bilateral cavitation 1 ( 5 % ) 2 ( 10 % ) Scientific Pierce , ill . , USA ) , which yielded a correlation Cavity classification 
coefficient R² of 0 . 99 . The concentration of IgM in serum 25 
samples ( in ug / ml ) was calculated based on this standard Absent 8 ( 40 % ) 9 ( 45 % ) Present < 4 cm 5 ( 25 % ) 4 ( 20 % ) 
curve . High , medium , and low IgM level control samples Present 4 cm 7 ( 35 % ) 7 ( 35 % ) 
were included in each assay . Assays with control sample Extent of Chest x - ray involvement 
results outside two standard deviations were discarded and 0 ( 0 % ) 3 ( 15 % ) repeated . Moderate 14 ( 70 % ) 7 ( 35 % ) Statistical Analyses Extensive 6 ( 30 % ) 10 ( 50 % ) 
All statistical analyses were conducted with STATA ( Ver Any bilateral abnormalities 8 ( 40 % ) 12 ( 60 % ) 
AFB smear 
sion 11 , STATA Corp . , Texas ) . The two - sample Wilcoxon 
rank - sum test was used to compare lipid - specific IgM con - 36 2 + 4 ( 20 % ) 0 ( 0 % ) 
centration differences between fast and slow responders ( at 6 ( 30 % ) 7 ( 35 % ) 10 ( 50 % ) 13 ( 65 % ) baseline and at the end of intensive phase of treatment ) . A Days to detection ; median ( IQR ) 5 . 84 ( 2 . 54 ) 5 . 83 ( 2 . 38 ) 
step - wise procedure was performed to test for the following TB treatment 
variables suspected to be biologically relevant to IgM anti 
body response during treatment : age , gender , body mass 40 Received pretreatment 4 ( 20 % ) 1 ( 5 % ) 40 Days of pretreatment 0 ( 0 % ) 0 ( 0 % ) index ( BMI ), bilateral abnormalities , acid - fast bacillus 
( AFB ) smear status at baseline , cavitary disease , and disease 
severity . Variables were added to the basic model in a The IgM anti - phospholipid antibody response was highly 
stepwise fashion . Variables were eliminated if they failed to variable among these patients . A global analysis of our 
achieve significance at the 5 % level from the full model to 45 sample set showed heterogeneous results for all five anti 
obtain the best fit and simplest model that included cavity phospholipid IgM levels , regardless of culture conversion 
classification and disease severity as significant variables . status . A comparison of the change in IgM antibody levels 
The Wilcoxon signed - rank nonparametric test was used to between TB patients who remained culture positive and 
compare lipid - specific antibody differences between groups those who culture converted after 40 doses of intense 
for cavity and disease severity variables . All experiments 30 ants 50 therapy , revealed no significant differences using a two 
were conducted with IRB approval from the Committee for sample t - test . 
Protection of Human Subjects at UC Berkeley ( UCB # 2010 The multi - variable model included age , gender , body 
mass index , bilateral abnormalities , smear status at baseline , 06 - 1752 ) . cavity extension and disease extension . This model revealed Results no contribution of the variables to changes in antibody levels The CDC - TBTC sample set was composed of 40 HIV upon treatment completion . Thus , we opted to use a simpler 
negative patients ( 29 males and 11 females ) with smear and model using " cavity classification ” as a proxy for disease 
culture confirmed pulmonary TB . The average age was 29 severity and adjusted for " age ” . The “ cavity classification ” 
years ( range 19 to 53 years of age ) . Fifty - five percent of variable showed a uniform distribution across three catego 
these patients were non - smokers , non - alcoholics , and non 60 ries , including no cavity ( n = 17 ) , small cavity ( n = 9 ) , and 
drug users ( Table 1 ) . Patients with negative culture after 2 large cavity ( n = 14 ) . This simpler model allowed us to study 
months of treatment showed a higher BMI . Three levels of the IgM anti - phospholipid antibodies as a biomarker for TB 
disease severity were identified based on the extent of treatment response , despite the variability of the antibody 
radiological findings in chest X - ray at TB diagnosis includ - levels within our sample set . 
ing : limited ( n = 3 ) , moderate ( n = 21 ) , and extensive ( n = 16 ) ; 65 Analysis of this simpler model consistently revealed IgM 
and whether or not cavitary lesions were present : cavity anti - phospholipids antibodies to decrease among TB 
( n = 23 ) and no cavity ( n = 17 ) ( Table 1 ) . patients with no lung cavities . Specifically , the mean IgM 
3 + 
4 + 
St . 
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concentration decreased significantly in four of the five USA ) . The ethanol was allowed to dry for thirty minutes , 
phospholipids , including PE , PI , PTC and SL ( paired t - stu - and the membrane was washed with phosphate - buffered 
dent p = 0 . 008 , 0 . 016 , 0 . 020 , and 0 . 043 respectively ) . The saline ( PBS ) ( 1M , pH 7 . 2 ) . The membrane was then blocked 
distribution of delta change among all patients was scattered with 5 ul of 2 % bovine serum albumin ( BSA ) ( low fatty 
due to the presence of outliers in the cavity classification 5 acid , low endotoxin , low IgG ) ( US Biological , Swampscott , 
categories . The median values of antibody change were Mass . , USA ) for one hour . The membrane was washed again 
analyzed with a two - sample Wilcoxon rank - sum test . This with PBS ; and 5 ul of undiluted patient serum was applied 
revealed a significant decrease for all five lipids , CL , PI , PE , to each well and incubated for two hours in a wet chamber 
PTC , and SL in non - cavitary TB patients ( Wilcoxon rank to prevent evaporation . The membrane was washed again , 
sum test p = 0 . 036 , 0 . 006 , 0 . 001 , 0 . 007 , 0 . 040 respectively , 10 and a 5 ul suspension of the anti - IgM - coated magnetic bead 
see FIG . 1 ) . The antibody level reduction was different for was added to each well and incubated for twenty minutes , 
each lipid . Specifically , we observed a 22 . 7 % , 11 . 1 % , followed by another PBS wash . The membrane was then 15 . 4 % , 24 . 3 % and 18 . 0 % concentration reduction of IgM visualized with the unaided eye for rusty - colored spots in the 
anti - CL , PE , PI , PTC and SL , respectively . wells , which indicated a positive test reaction . A visual On the other hand , patients with cavitary TB showed an 15 representation of the assay is shown in FIG . 3 . 
overall increase in the IgM anti - phospholipid antibody The intensity of the color at each spot was quantitatively response following anti - TB drug treatment . A significant compared by software ImageJ . Table 3 summarizes results increase was observed in anti - PE antibody levels ( p = 0 . 025 , based on serum samples obtained from 29 culture - confirmed 95 % C . I . - 0 . 091 , - 0 . 004 ) . 
FIG . 1 : Plots of the Change of IgM Anti - Phospholipids 20 a nids 20 cases of TB ( TB patients ) , 16 patients with pulmonary 
Antibody Levels after 40 Doses of Intense Anti - TB Drug disease other than TB ( OPD ) , and 19 healthy subjects whose 
Therapy . tuberculin skin test was negative , indicating no evidence of 
Antibody levels were determined by in - house ELISA TB infection ( TST - ) . 
assay ; and results are shown in concentration ( ug / ml ) . The Table 3 . Results of mLISA based on serum samples tested 
panels compare the antibody decrease in Cavitary TB 25 against cardiolipin ( CL ) , phosphotidylethanolamine ( PE ) , 
patients vs Non - cavitary TB patients for each of the five phophatidylinositol ( PI ) , phosphotidylcholine ( PTC ) , and 
phospholipids including Cardiolipin ( CL ) ; phosphatidyl sphingolipid ( SL ) embedded in PET wells . The well images 
ethanolamine ( PE ) ; Phosphatidyl Inositol ( PI ) ; Phosphatidyl were converted into 16 - bit black and white photos , and 
Choline ( PTC ) ; Sphingolipid ( SL ) . particle density was measured in each well . The readings 
We evaluated our biomarker test ' s ability to identify 30 from 4 spots on one piece of membrane ( 2x2 cm ) were 
successful treatment response in non - cavitary TB patients . A combined to calculate an average reading per membrane . 
positive biomarker test was defined as a decrease in IgM Student T test was used to compare the results . 
anti - phospholipid antibodies and a negative test as an 
increase or no change in IgM anti - phospholipid antibodies . TABLE 3 The outcome was successful treatment response . The sen - 33 
sitivity values for the phospholipid - antibody biomarker test Comparison Groups CL PE PI P TC SL 
were 88 . 2 % , 70 . 6 % , 76 . 5 % , 88 . 2 % and 76 . 5 % for IgM TB patient v . TST - < 0 . 001 < 0 . 001 < 0 . 001 < 0 . 001 < 0 . 001 
anti - CL , PE , PI , PTC and SL , respectively ( Table 2 ) . Taken TB patient v . OPD < 0 . 001 0 . 009 0 . 014 0 . 031 0 . 072 together , the mean sensitivity reached 80 % . TST - v . OPD 0 . 049 0 . 014 0 . 003 0 . 004 0 . 002 
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TABLE 2 
Biomarker test evaluation for monitoring treatment response 
in non - cavitary TBC . 
Non - Cavitary 
TB decreased Sensitivity % 
While the present invention has been described with 
reference to the specific embodiments thereof , it should be 
understood by those skilled in the art that various changes 
45 may be made and equivalents may be substituted without 
departing from the true spirit and scope of the invention . In 
addition , many modifications may be made to adapt a 
particular situation , material , composition of matter , pro 
cess , process step or steps , to the objective , spirit and scope 
50 of the present invention . All such modifications are intended 
to be within the scope of the claims appended hereto . 
CL 
PE 
PI 
PtC 
SL 
15 / 17 
12 / 17 
13 / 17 
15 / 17 
13 / 17 
88 . 2 
70 . 6 
76 . 5 
88 . 2 
76 . 5 
" Number of non - cavitary TB patients that showed a decrease in IgM anti - phospholipid 
antibody levels . Values for sensitivity were determined for each lipid using contingency What is claimed is : 
table analysis . 1 . A method of determining response in a human indi 
55 vidual to treatment for a non - cavitary Mycobacterium tuber 
Example 2 : Detection of IgM Antibody to M . culosis infection , the method comprising determining the 
tuberculosis Lipids Using a Magnetic Bead - Linked level of IgM specific for two or more different M . tubercu 
Immunosorbent Assay losis lipids in a biological sample obtained from the indi 
vidual , wherein a level of M . tuberculosis lipid - specific IgM 
A magnetic bead - linked immunosorbent assay ( mLISA ) 60 in the biological sample that is lower than a pre - treatment 
was developed to detect IgM antibody to M . tuberculosis level in a control sample of the same type as the biological 
lipids . The mLISA assay is depicted schematically in FIG . 2 . sample indicates that the individual is responding positively 
Streptavidin - coated magnetic beads linked to biotin - conju - to the treatment . 
gated anti - IgM antibody were used . A small drop ( 2 micro 2 . The method of claim 1 , wherein the two or more M . 
liters ) of phospholipid solution in ethanol was spotted onto 65 tuberculosis lipids are selected from cardiolipin , phosphati 
wells made by a 2 . 5 mm biopsy punch on a 2x2 cm piece of dylinositol , phosphatidylethanolamine , phosphatidylcho 
polyester terephthalate ( PET ) membrane ( Rogers Corp . , IL , line , and sphingolipid . 
19 
Plex . 
US 9 , 835 , 624 B2 
20 
3 . The method of claim 1 , wherein the biological sample detecting IgM specific for two or more different Mycobac 
is blood , a blood fraction , cerebrospinal fluid , pleural fluid , terium tuberculosis lipids in a liquid biological sample 
bronchoalveolar lavage fluid , or saliva . obtained from the individual , wherein the presence in the 
4 . The method of claim 1 , wherein the two or more biological sample of IgM specific for two or more different 
different M . tuberculosis lipids are selected from phospha - 5 Mycobacterium tuberculosis lipids indicates the presence in 
tidylinositol , phosphatidylethanolamine , phosphatidylcho - the individual of Mycobacterium tuberculosis , and wherein 
line , and sphingolipid . the step of detecting the IgM comprises : 5 . An assay device for use in detecting IgM specific for a a ) contacting two or more different , immobilized Myco Mycobacterium tuberculosis lipid in a liquid biological bacterium tuberculosis lipids with the liquid biological sample obtained from an individual , the device comprising 10 sample , wherein any IgM specific for the immobilized 
a matrix defining an axial flow path , the matrix comprising : Mycobacterium tuberculosis lipids binds the immobi i ) a zone one comprising a sample receiving zone at an lized Mycobacterium tuberculosis lipids , forming an upstream end of the flow path configured to receive the 
fluid sample ; immobilized Mycobacterium tuberculosis lipid - IgM 
ii ) a zone three comprising one or more test zones 15 complex ; and 
positioned within the flow path and downstream from b ) contacting the immobilized Mycobacterium tuberculo 
zone one , each of said one or more test zones com sis lipid - IgM complex with detectably labeled anti - IgM 
prising a Mycobacterium tuberculosis lipid immobi antibody , wherein the anti - IgM antibody forms a com 
lized in each of said test zones , wherein each of said plex with the immobilized Mycobacterium tuberculosis 
immobilized lipids is capable of binding a M . tubercu - 20 lipid - IgM ; and 
losis lipid - specific IgM present in said liquid sample to c ) detecting the anti - IgM antibody present in the anti 
form an immobilized IgM - lipid complex ; IgM - immobilized Mycobacterium tuberculosis lipid iii ) a zone two comprising a label zone comprising a IgM complex . 
detectably labeled antibody specific for human IgM , 12 . The method of claim 11 , wherein the two or more 
wherein the label zone is positioned within the flow 25 different , immobilized M . tuberculosis lipids are selected 
path configured to receive the sample from zone one from cardiolipin , phosphatidylinositol , phosphatidyletha 
and is downstream of zone one and upstream of zone nolamine , phosphatidylcholine , and sphingolipid . 
three , wherein the detectably labeled antibody is 13 . The method of claim 11 , wherein the biological 
capable of binding an IgM present in an immobilized sample is blood , a blood fraction , cerebrospinal fluid , pleural IgM - lipid complex to form a labeled immobilized 30 fluid , bronchoalveolar lavage fluid , or saliva . IgM - lipid complex , and wherein the detectably labeled 14 . The method of claim 11 , wherein the anti - IgM anti antibody is capable of binding to the human IgM body is coupled to a magnetic bead , an enzyme that gener present in the liquid sample to form a labeled antibody / 
ates a fluorescent product , an enzyme that generates a human IgM complex that is configured to flow to the 
one or more test zones of zone three ; and 35 colored product , a fluorescent polypeptide , or a chromogenic 
iv ) a zone four comprising one or more control zones polypeptide . 
positioned within the flow path and downstream from 15 . The method of claim 14 , wherein the anti - IgM anti 
zone one , each of said one or more control zones body is coupled to a magnetic bead . 16 . The method of claim 15 , wherein coupling of the comprising a positive control comprising immobilized 
human IgM in a known amount , or a negative control 404 an anti - IgM antibody to the magnetic bead comprises binding of an anti - IgM antibody covalently linked to a biotin to the comprising no M . tuberculosis lipids , wherein zone 
four is configured to receive the sample from zone one , magnetic bead coated with a streptavidin to form a stable 
wherein the M . tuberculosis lipid - specific IgM is detected anti - IgM magnetic bead complex . 17 . The method of claim 15 , wherein coupling of the when the detectably labeled antibody specific for 
human IgM is bound to the immobilized IgM - lipid 45 ani is anti - IgM antibody to the magnetic bead comprises binding of an anti - IgM antibody to the magnetic bead , wherein the complex . 
6 . A kit for determining the level of IgM specific for two magnetic bead is cross - linked to a protein G or a protein A . 18 . The method of claim 11 , wherein said individual is or more different Mycobacterium tuberculosis lipids in a 
biological sample obtained from an individual , the kit com co - infected with human immunodeficiency virus . 
prising : 19 . The method of claim 11 , wherein said individual has 
a ) an anti - IgM antibody comprising a detectable label : non - cavitary lung disease . 20 . The method of claim 11 , wherein the labeled antibody and 
b ) a panel of two or more different Mycobacterium is mobilizable in the presence of the liquid sample . 
tuberculosis lipids . 21 . The method of claim 11 , wherein the labeled anti - IgM 
7 . The kit of claim 6 , further comprising purified human 55 man 55 antibody comprises a label selected from the group consist 
IgM for use in generating a standard curve . a ) a chemiluminescent agent ; 8 . The kit of claim 6 , further comprising a panel of 
positive control IgM antibodies specific for the lipids in the b ) a particulate label ; 
panel . c ) a colorimetric agent ; 
9 . The kit of claim 6 , further comprising an insoluble 60 d ) an energy transfer agent ; 
support having the panel of lipids attached thereto . e ) an enzyme ; 
10 . The kit of claim 6 , wherein the panel of lipids f ) a fluorescent agent ; and 
comprises cardiolipin , phosphatidylinositol , phosphatidyle g ) a radioisotope . 22 . The method of claim 21 , wherein the particulate label thanolamine , phosphatidylcholine , and sphingolipid . 
. A method for detecting the presence of Mycobacte - 65 15 0 comodal gold . 
rium tuberculosis in an individual , the method comprising * * * * * 
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